Xylose as a carrier for boron containing compounds.
A xylosylated carborane was synthesized by standard carbohydrate methodology and tested on normal HFL-1 cells as well as transformed T24 cells. The xylosylated carborane initiated glycosaminoglycan (GAG) synthesis in both cell lines and treatment with the carborane gave a pronounced translocation of proteoglycans to the nuclei of T24 cells. However, most of the boron-containing compounds were secreted to the medium. We conclude that xylosides carrying carboranes are not suitable for boron neutron capture therapy (BNCT) for T24 cells. However, the uptake of boron-containing xyloside, the GAG priming capacity, and the nuclear translocation of glypican-1 make this xyloside a candidate for further investigation for selectivity toward other tumor cell lines.
Jacobsson
Mårten
M
Organic Chemistry, Lund University, PO Box 123, SE-221 00 Lund, Sweden.
Winander
Cecilia
C
Mani
Katrin
K
Ellervik
Ulf
U
D000818:Animals; D001665:Binding Sites; D001896:Boron Compounds / Q000008:administration & dosage* / Q000138:chemical synthesis; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002461:Cell Line, Transformed / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects; D004337:Drug Carriers / Q000008:administration & dosage* / Q000138:chemical synthesis; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D008956:Models, Chemical; D013329:Structure-Activity Relationship; D014994:Xylose / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000138:chemical synthesis
D001896:Boron Compounds; D004337:Drug Carriers; D014994:Xylose